帕洛诺司琼联合地塞米松在预防胃癌化疗中奥沙利铂所致恶心呕吐的疗效观察-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

帕洛诺司琼联合地塞米松在预防胃癌化疗中奥沙利铂所致恶心呕吐的疗效观察

Effect of Polonosetron Plus Dexamethasone in Preventing Oxaliplatin-Based Chemotherapy induced Nausea and Vomiting in Gastric Cancer

ES评分 0 浏览量：677 下载量：0

全文阅读下载引用收藏

DOI	10.12208/j.ijcr.20220474
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2022, 6(10)
作者	薛彩花,崔雯*,
作者单位	青岛市黄岛区中心医院肿瘤科山东青岛 ;
摘要	回顾性分析帕洛诺司琼联合地塞米松在预防胃癌化疗中奥沙利铂所致恶心、呕吐的疗效观察。方法选择2020年1月～2022年1月在黄岛区中心医院诊治的胃癌患者32例，均应用含奥沙利铂的化疗方案，其中观察组16列，对照组16例。观察组化疗前30分钟应用帕洛诺司琼，对照组化疗前30分钟应用托烷司琼，两组均于化疗前第1天、化疗后第2、3天静脉应用地塞米松。结果两组患者在急性期的呕吐完全缓解率差异无统计学意义（P>0.05），但在延迟期和全期差异均有统计学意义（P<0.05）。结论帕洛诺司琼联合地塞米松防治胃癌化疗中奥沙利铂所导致的延迟期及全期的恶心呕吐的疗效优于托烷司琼。
Abstract	Objective To retrospectively analyze the Effect of Polonosetron Plus Dexamethasone in Preventing Oxaliplatin-Based Chemotherapy induced Nausea and Vomiting in Gastric Cancer. Methods 32 patients with gastric cancertreated in the Huangdao Central Hospital from January 2020 to January 2022 were enrolled in this trial, through Oxaliplatin-Based Chemotherapy.16 cases（the observation group)received plalonosetron before 30 min administration of oxaliplatin.16 cases（the controlgroup) received tolansetronbefore 30 min administration of oxaliplatin. Dexamethasone was given intravenously on day 1 before chemotherapy and day 2 and 3 after chemotherapy in the two groups. Results There was no statistically significant difference in the complete remission rate of vomiting between 2 groups in the acute phase (P>0.05), but there was statistically significant difference in the delayed phase and the whole phase (P<0.05). Conclusion The efficacy of palonosetron combined with dexamethasone in the treatment of delayed phase and whole phase nausea and vomiting induced by oxaliplatin in gastric cancer chemotherapy is better than that of tolansetron.
关键词	帕洛诺司琼；托烷司琼；地塞米松；化疗；奥沙利铂
KeyWord	Palonosetron; Toanisetron; Dexamethasone; Chemotherapy; Oxaliplatin
基金项目
页码	50-52

参考文献
相关文献

[1] HERRSTEDT J,ROILA F,WARR D, et al. 2016 Updated MASCC/ ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy
[J]. Supportive Care in Cancer, 2017, 25(1):277-288.

[2] 郭芷君,徐峰.化学治疗所致恶心呕吐分类与药物治疗的研究进展
[J].中国药业,2020,29(22):1-6.

[3] 王涵,王洪学,谢伟敏,等.重复使用 5-HT3受体拮抗剂预防多日化疗相关性恶心呕吐的疗效和安全性分析
[J].中国肿瘤临床,2017(13):125-126.

[4] 聂微,严芝强,成兴真,等.奥沙利铂通过自噬诱导胃癌细胞耐药的机制
[J].实用医学杂志,2022,38(7):828-35.

[5] 张顺同. 帕洛诺司琼胶囊、注射液及托烷司琼注射液预防HEC、MEC所致CINV的成本效果分析
[D]. 河南:郑州大学,2017.

[6] Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
[J]. J Natl Compr Canc Netw. 2022;20(2): 167-192.

[7] Mosa ASM, Hossain AM, Yoo I. A dynamic prediction engine to prevent chemotherapy-induced nausea and vomiting
[J]. Artif Intell Med. 2020;109:101925.

[8] 中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会.中国肿瘤药物治疗相关恶心呕吐防治专家共识（2022年版）
[J].中华医学杂志,2022,102(39):3080-3094.

[9] Kuchuk I, Bouganim N, Beusterien K, et al. Preference weights for chemotherapy sideeffects from the perspective of women with breast cancer
[J]. Breast Cancer ResTreat,2013,142(1):101-7.

[10] Brenner H, Rothenbacher D, Arndt V, et al. Epidemiology of stomach cancer
[J]. Methods Mol Biol, 2009, 472 (5450):1567-1568.

[11] Harada K,Yamashita K,Iwatsuki M,et al.Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis
[J]. Expert Rev Clin Pharmacol.2022;15(1):43-49.

[12] Park JK，Seo JS，Lee SKet alCombinatorial antitumor activity of oxaliplatin with epigenetic modifying agents, 5-Aza-CdR and FK228,in human gastric cancer cells
[J]. Biomol Ther,2018,26 (6) : 591－598

[13] Cheng Y, Wu Z, Shi L, et al. Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
[J]. EClinicalMedicine. 2022;49: 101480.

[14] Lorusso V,Spedicato A,Petrucelli L,et al.Single dose of palonoseLron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients created with highly eme-togenic chemotherapy ( HEC)
[J].Support CareCancer.2009,17( 12):1469-1473

[15] Aogi K, Takeuchi H, Saeki T, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis
[J]. Int J Clin Oncol. 2021;26(1):1-17.

[16] Cho E, Kim DH, Shin S, et al. Efficacy of Palonosetron- Dexamethasone Combination Versus Palonosetron Alone for Preventing Nausea and Vomiting Related to Opioid-Based Analgesia: A Prospective, Randomized, Double-blind Trial
[J]. Int J Med Sci. 2018;15(10): 961-968.

引用本文

薛彩花,崔雯*. 帕洛诺司琼联合地塞米松在预防胃癌化疗中奥沙利铂所致恶心呕吐的疗效观察 [J]. 国际临床研究杂志. 2022; 6; (10). 50 - 52.

文献评论

相关学者

相关机构